March 10 Through April 30, 2020, Public Meetings; Postponement, Cancellation, or Remote Only

---
identifier: "/us/fr/2020-05743"
source: "fr"
legal_status: "authoritative_unofficial"
title: "March 10 Through April 30, 2020, Public Meetings; Postponement, Cancellation, or Remote Only"
title_number: 0
title_name: "Federal Register"
section_number: "2020-05743"
section_name: "March 10 Through April 30, 2020, Public Meetings; Postponement, Cancellation, or Remote Only"
positive_law: false
currency: "2020-03-19"
last_updated: "2020-03-19"
format_version: "1.1.0"
generator: "[email protected]"
agency: "Health and Human Services Department"
document_number: "2020-05743"
document_type: "notice"
publication_date: "2020-03-19"
agencies:
  - "Health and Human Services Department"
  - "Food and Drug Administration"
fr_citation: "85 FR 15789"
fr_volume: 85
docket_ids:
  - "Docket Nos. FDA-2020-N-0001, FDA-2020-N-0255, FDA-2020-N-0256, FDA-2020-N-0259, FDA-2018-N-4337"
fr_action: "Notice."
---


#  March 10 Through April 30, 2020, Public Meetings; Postponement, Cancellation, or Remote Only

**AGENCY:**

Food and Drug Administration, HHS.

**ACTION:**

Notice.

**SUMMARY:**

The Food and Drug Administration is announcing that certain meetings involving the Center for Drug Evaluation and Research (CDER) from March 10 through April 30, 2020, are postponed, cancelled, or modified to take place remotely.

**DATES:**

For dates that have been either postponed or cancelled, see table 1 in the *SUPPLEMENTARY INFORMATION* section.

**FOR FURTHER INFORMATION CONTACT:**

Kim Thomas, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, Rm. 6282, Silver Spring, MD 20993-0002, 301-796-2357, *[email protected].*

**SUPPLEMENTARY INFORMATION:**

Certain public meetings involving CDER from March 10 through April 30, 2020, are postponed, cancelled, or modified to take place remotely due to extenuating circumstances. The meetings that are postponed or canceled as part of this notice are listed in table 1. If a meeting is rescheduled, information about the rescheduled meeting will be provided in the future. The meeting that will no longer take place in person and instead take place by webcast only as part of this notice is listed in table 2. [^1]

[^1] Up-to-date information about public meetings involving CDER is available on the internet at *https://www.fda.gov/drugs/news-events-human-drugs/meetings-conferences-workshops-drugs.*

| Meeting type | Meeting title | Original meeting date | Docket No. |  |
| --- | --- | --- | --- | --- |
| Public Meeting | Patient-Focused Drug Development for Stimulant Use Disorder | Mar. 10, 2020 | FDA-2020-N-0259 | 85 FR 8877, Feb. 18, 2020. |
| Public Meeting | Patient-Focused Drug Development for Vitiligo | Mar. 30, 2020 | FDA-2020-N-0255 | 85 FR 8004, Feb. 12, 2020. |
| Public Meeting | Scientific and Ethical Considerations for the Inclusion of Pregnant Women in Clinical Trials | Apr. 16, 2020 | FDA-2020-N-0001 | 85 FR 14207, Mar. 11, 2020. |
| Public Meeting | Prescription Drug User Fee Act of 2017; Electronic Submissions and Data Standards | Apr. 22, 2020 | FDA-2018-N-4337 | 85 FR 6547, Feb. 5, 2020. |

| Meeting type | Meeting title | Original meeting date | Docket No. | citation | Remote information |
| --- | --- | --- | --- | --- | --- |
| Public Meeting | United States Food and Drug Administration and Health Canada Joint Regional Consultation on the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use | Apr. 3, 2020 | FDA-2020-N-0256 | 85 FR 13659, Mar. 9, 2020 |  |

Dated: March 16, 2020.

Lowell J. Schiller,

Principal Associate Commissioner for Policy.